FOLH1 and prostate cancer: To determine the efficacy of A10-liposome-CRISPR/Cas9 chimeras in vivo, we detected the ability of the A10-liposome-CRISPR/Cas9 chimeras to retard xenograft tumor growth in athymic mice derived from PSMA-positive human prostate cancer cells (LNCap).